{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T03:43:41Z","timestamp":1775619821317,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Addictive Behaviors"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.addbeh.2026.108659","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:27:12Z","timestamp":1773188832000},"page":"108659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Drug positivity, co-detection patterns, and demographic predictors in patients seeking substance use disorder treatment, United States, 2023"],"prefix":"10.1016","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0599-780X","authenticated-orcid":false,"given":"Joohyun","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin K.","family":"Niles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5799-1787","authenticated-orcid":false,"given":"Bruce A.","family":"Goldberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9655-9033","authenticated-orcid":false,"given":"Robert C.","family":"Orellana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Casey Lyons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1028-1494","authenticated-orcid":false,"given":"Grant T.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.addbeh.2026.108659_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108518","article-title":"Social vulnerabilities for substance use: Stressors, socially toxic environments, and discrimination and racism","volume":"188","author":"Amaro","year":"2021","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.addbeh.2026.108659_b0010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion - comment - rejoinder","volume":"16","author":"Brown","year":"2001","journal-title":"Statistical Science"},{"key":"10.1016\/j.addbeh.2026.108659_b0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.drugalcdep.2017.10.007","article-title":"Treatment for opioid use and outcomes in older adults: A systematic literature review","volume":"182","author":"Carew","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"34","key":"10.1016\/j.addbeh.2026.108659_b0020","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.15585\/mmwr.mm7134a1","article-title":"Patient-level and county-level trends in nonfatal opioid-involved overdose emergency medical services encounters - 491 counties, United States, January 2018-March 2022","volume":"71","author":"Casillas","year":"2022","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.addbeh.2026.108659_b0025","unstructured":"Centers for Disease Control and Prevention, 2024a. CDC Drug Overdose Surveillance and Epidemiology (DOSE) System: Nonfatal Overdose Emergency Department and Inpatient Hospitalization Discharge Data. https:\/\/www.cdc.gov\/overdose-prevention\/data-research\/facts-stats\/dose-dashboard-nonfatal-discharge-data.html (accessed January 23, 2025)."},{"key":"10.1016\/j.addbeh.2026.108659_b0030","unstructured":"Centers for Disease Control and Prevention, 2024b. CDC Drug Overdose Reporting System (SUDORS). Final Data. https:\/\/www.cdc.gov\/overdose-prevention\/data-research\/facts-stats\/sudors-dashboard-fatal-overdose-data.html (accessed January 23, 2025)."},{"key":"10.1016\/j.addbeh.2026.108659_b0035","unstructured":"Centers for Disease Prevention and Control, 2025. CDC Reports Nearly 24% Decline in U.S. Drug Overdose Deaths. https:\/\/www.cdc.gov\/media\/releases\/2025\/2025-cdc-reports-decline-in-us-drug-overdose-deaths.html (accessed April 25, 2025)."},{"issue":"1","key":"10.1016\/j.addbeh.2026.108659_b0040","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1038\/s41467-023-40637-8","article-title":"Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: A longitudinal trend study","volume":"14","author":"Chan","year":"2023","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.addbeh.2026.108659_b0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41380-020-00949-3","article-title":"Polysubstance use in the U.S. opioid crisis","volume":"26","author":"Compton","year":"2021","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.addbeh.2026.108659_b0050","unstructured":"CONGRESS.GOV, 2022. H.R.2617 - Consolidated Appropriations Act, 2023. https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/2617 (accessed January 17 2025)."},{"key":"10.1016\/j.addbeh.2026.108659_b0055","doi-asserted-by":"crossref","unstructured":"Costales, B., Goodin, A.J., 2021. Outpatient Off-Label Gabapentin Use for Psychiatric Indications Among U.S. Adults, 2011-2016. Psychiatr Serv 72(11), 1246-1253.","DOI":"10.1176\/appi.ps.202000338"},{"key":"10.1016\/j.addbeh.2026.108659_b0060","series-title":"Fighting the Opioid Epidemic","first-page":"113","article-title":"Chapter 6 - poppy seed defense and workplace drug testing: Does it work in the court?","author":"Dasgupta","year":"2020"},{"key":"10.1016\/j.addbeh.2026.108659_b0235","unstructured":"Designing Surveys for Evaluations and Research, 2022. Survey Error and Response Bias Problems. https:\/\/edtechbooks.org\/designing_surveys\/validity_threats (accessed February 26, 2025)."},{"issue":"3","key":"10.1016\/j.addbeh.2026.108659_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain - United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR - Recommendations and Reports"},{"key":"10.1016\/j.addbeh.2026.108659_b0070","unstructured":"Federal Register, 2021. Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder. https:\/\/www.federalregister.gov\/documents\/2021\/04\/28\/2021-08961\/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder (accessed January 17, 2025)."},{"issue":"2","key":"10.1016\/j.addbeh.2026.108659_b0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1360-0443.2003.00632.x","article-title":"The utility of drug testing in epidemiological research: Results from a general population survey","volume":"99","author":"Fendrich","year":"2004","journal-title":"Addiction"},{"issue":"12","key":"10.1016\/j.addbeh.2026.108659_b0080","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/add.16318","article-title":"Charting the fourth wave: Geographic, temporal, race\/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021","volume":"118","author":"Friedman","year":"2023","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.addbeh.2026.108659_b0085","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/10600280211028262","article-title":"Pronounced regional disparities in united states methadone distribution","volume":"56","author":"Furst","year":"2022","journal-title":"The Annals of Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.addbeh.2026.108659_b0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.addbeh.2026.108659_b0095","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000001457","article-title":"Individuals dispensed buprenorphine in the united states before and after federal policy changes aimed at increasing access","author":"Guy","year":"2025","journal-title":"Journal of Addiction Medicine"},{"issue":"4","key":"10.1016\/j.addbeh.2026.108659_b0100","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamapsychiatry.2020.4402","article-title":"Trends in US emergency department visits for mental health, overdose, and violence outcomes before and during the COVID-19 pandemic","volume":"78","author":"Holland","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.addbeh.2026.108659_b0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.41063","article-title":"Fentanyl, heroin, methamphetamine, and cocaine analyte concentrations in urine drug testing specimens","volume":"7","author":"Huhn","year":"2024","journal-title":"JAMA Network Open"},{"issue":"3","key":"10.1016\/j.addbeh.2026.108659_b0110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/ADM.0000000000000323","article-title":"Appropriate use of drug testing in clinical addiction medicine","volume":"11","author":"Jarvis","year":"2017","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.addbeh.2026.108659_b0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nyas.14688","article-title":"Methamphetamine use in the United States: Epidemiological update and implications for prevention, treatment, and harm reduction","volume":"1508","author":"Jones","year":"2022","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"17","key":"10.1016\/j.addbeh.2026.108659_b0120","doi-asserted-by":"crossref","first-page":"388","DOI":"10.15585\/mmwr.mm6817a3","article-title":"Drug overdose deaths involving cocaine and psychostimulants with abuse potential - United States, 2003-2017","volume":"68","author":"Kariisa","year":"2019","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"1","key":"10.1016\/j.addbeh.2026.108659_b0125","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/08897077.2021.1986768","article-title":"COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership","volume":"43","author":"Levander","year":"2022","journal-title":"Substance Abuse"},{"issue":"5S","key":"10.1016\/j.addbeh.2026.108659_b0130","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jpainsymman.2005.01.004","article-title":"Opioid metabolites","volume":"29","author":"Lotsch","year":"2005","journal-title":"Journal of Pain and Symptom Management"},{"issue":"20","key":"10.1016\/j.addbeh.2026.108659_b0135","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/jama.2023.5038","article-title":"Changes in waivered clinicians prescribing buprenorphine and prescription volume by patient limit","volume":"329","author":"Luo","year":"2023","journal-title":"Journal of the American Medical Association"},{"issue":"4","key":"10.1016\/j.addbeh.2026.108659_b0140","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/10550887.2023.2293643","article-title":"Prevalence and drug use correlates of inadvertent fentanyl exposure among individuals misusing drugs in seven U.S. states","volume":"42","author":"Magura","year":"2024","journal-title":"Journal of Addictive Diseases"},{"issue":"6","key":"10.1016\/j.addbeh.2026.108659_b0145","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1213\/ANE.0000000000002565","article-title":"Role of urine drug testing in the current opioid epidemic","volume":"125","author":"Mahajan","year":"2017","journal-title":"Anesthesia and Analgesia"},{"key":"10.1016\/j.addbeh.2026.108659_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104063","article-title":"Understanding intentionality of fentanyl use and drug overdose risk: Findings from a mixed methods study of people who inject drugs in New York City","volume":"118","author":"McKnight","year":"2023","journal-title":"The International Journal on Drug Policy"},{"issue":"1","key":"10.1016\/j.addbeh.2026.108659_b0160","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/AJP.0b013e31817e13cc","article-title":"Utility and application of urine drug testing in chronic pain management with opioids","volume":"25","author":"Nafziger","year":"2009","journal-title":"The Clinical Journal of Pain"},{"issue":"S1","key":"10.1016\/j.addbeh.2026.108659_b0165","first-page":"S43","article-title":"The opioid epidemic within the COVID-19 pandemic: Drug testing in 2020","volume":"24","author":"Niles","year":"2021","journal-title":"Population Health Management"},{"key":"10.1016\/j.addbeh.2026.108659_b0175","doi-asserted-by":"crossref","unstructured":"Palamar, J.J., et al., 2024. National and regional trends in fentanyl seizures in the United States, 2017-2023. Int J Drug Policy, 104417.","DOI":"10.1016\/j.drugpo.2024.104417"},{"key":"10.1016\/j.addbeh.2026.108659_b0180","doi-asserted-by":"crossref","unstructured":"Pauly, N.J., et al., 2020. Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016. J Manag Care Spec Pharm 26(3), 246-252.","DOI":"10.18553\/jmcp.2020.26.3.246"},{"issue":"16","key":"10.1016\/j.addbeh.2026.108659_b0185","doi-asserted-by":"crossref","first-page":"282","DOI":"10.15585\/mmwr.mm7416a2","article-title":"Trends in suspected fentanyl-involved nonfatal overdose emergency department visits, by age group, sex, and race and ethnicity - United States, October 2020-March 2024","volume":"74","author":"Pickens","year":"2025","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"4","key":"10.1016\/j.addbeh.2026.108659_b0190","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1513\/AnnalsATS.202011-1415ED","article-title":"Regional variation in methamphetamine-associated pulmonary arterial hypertension: Who'd better call saul?","volume":"18","author":"Prohaska","year":"2021","journal-title":"Annals of the American Thoracic Society"},{"issue":"1","key":"10.1016\/j.addbeh.2026.108659_b0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5055\/jom.2009.0004","article-title":"The aging methadone maintenance patient: Treatment adjustment, long-term success, and quality of life","volume":"5","author":"Rajaratnam","year":"2009","journal-title":"Journal of Opioid Management"},{"key":"10.1016\/j.addbeh.2026.108659_b0200","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ajem.2024.08.033","article-title":"Gabapentinoid prescribing patterns and predictors utilizing neural networks: An analysis across emergency departments Nationwide between 2012 and 2021","volume":"85","author":"Ramdin","year":"2024","journal-title":"The American Journal of Emergency Medicine"},{"key":"10.1016\/j.addbeh.2026.108659_b0205","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2019.03.026","article-title":"Patterns of polysubstance use and overdose among people who inject drugs in Baltimore, Maryland: A latent class analysis","volume":"201","author":"Schneider","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.addbeh.2026.108659_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108700","article-title":"Trends in substances involved in polysubstance overdose fatalities in Maryland, USA 2003-2019","volume":"223","author":"Schneider","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.addbeh.2026.108659_b0215","first-page":"1","article-title":"Drug overdose deaths involving fentanyl, 2011-2016","volume":"68","author":"Spencer","year":"2019","journal-title":"National Vital Statistics Reports"},{"key":"10.1016\/j.addbeh.2026.108659_b0220","unstructured":"Substance Abuse and Mental Health Services Administration, 2021. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63 Publication No. PEP21-02-01-002. https:\/\/store.samhsa.gov\/sites\/default\/files\/pep21-02-01-002.pdf (accessed November 3, 2023)."},{"key":"10.1016\/j.addbeh.2026.108659_b0225","unstructured":"Substance Abuse and Mental Health Services Administration 2024a. Treatment Episode Data Set (TEDS) 2022: Admissions to and Discharges From Substance Use Treatment Services Reported By Single State Agencies. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt53160\/2022-teds-annual-report.pdf (accessed February 5, 2025)."},{"key":"10.1016\/j.addbeh.2026.108659_b0230","unstructured":"Substance Abuse and Mental Health Services Administration, 2024b. Substance Use Disorder Treatment: Methadone. https:\/\/www.samhsa.gov\/substance-use\/treatment\/options\/methadone (accessed January 27, 2025)."},{"issue":"48","key":"10.1016\/j.addbeh.2026.108659_b0240","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.15585\/mmwr.mm7348a2","article-title":"Detection of illegally manufactured fentanyls and carfentanil in drug overdose deaths - United States, 2021-2024","volume":"73","author":"Tanz","year":"2024","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.addbeh.2026.108659_b0245","unstructured":"The Recovery Village, 2024. How Age Affects Drug Addiction. https:\/\/www.therecoveryvillage.com\/drug-addiction\/affects-age\/ (accessed January 27, 2025)."},{"key":"10.1016\/j.addbeh.2026.108659_b0250","unstructured":"U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, 2022. Early Changes in Waivered Clinicians and Utilization of Buprenorphine for Opioid Use Disorder After Implementation of the 2021 HHS Buprenorphine Practice Guidelines. https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/facbce1704035fded1034192d148304d\/buprenorphine-practice-guideline-early-impacts.pdf (accessed March 13, 2025)."},{"key":"10.1016\/j.addbeh.2026.108659_b0255","unstructured":"U.S. Drug Enforcement Administration., 2023. National Forensic Laboratory Information System: NFLIS-Drug 2022 annual report. https:\/\/www.nflis.deadiversion.usdoj.gov\/nflisdata\/docs\/2022NFLIS-DrugAnnualReport.pdf (accessed March 24, 2025)."},{"key":"10.1016\/j.addbeh.2026.108659_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2023.100150","article-title":"Community overdose surveillance: Fentanyl involvement in overdose deaths in rural Michigan","volume":"7","author":"Victor","year":"2023","journal-title":"Drug and Alcohol Dependence Reports"},{"issue":"6","key":"10.1016\/j.addbeh.2026.108659_b0265","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.15425","article-title":"Analysis of urine drug test results from substance use disorder treatment practices and overdose mortality rates, 2013-2020","volume":"5","author":"Whitley","year":"2022","journal-title":"JAMA Network Open"}],"container-title":["Addictive Behaviors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460326000699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460326000699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T02:44:12Z","timestamp":1775616252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306460326000699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":51,"alternative-id":["S0306460326000699"],"URL":"https:\/\/doi.org\/10.1016\/j.addbeh.2026.108659","relation":{},"ISSN":["0306-4603"],"issn-type":[{"value":"0306-4603","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug positivity, co-detection patterns, and demographic predictors in patients seeking substance use disorder treatment, United States, 2023","name":"articletitle","label":"Article Title"},{"value":"Addictive Behaviors","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addbeh.2026.108659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108659"}}